Tabrecta (capmatinib) for the Treatment of Non-Small Cell Lung Cancer (NSCLC)
Tabrecta™ works as a Mesenchymal-epithelial transition (MET) inhibitor. Credit: Novartis Pharmaceuticals Corporation.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more